Form 4: Zenas BioPharma Director Acquires Shares
Statement of Changes in Beneficial Ownership
Director Lu Hongbo acquired 3,768 shares of Zenas BioPharma common stock on March 31, 2026, for $18.63 per share.
Summary
- Lu Hongbo, a Director at Zenas BioPharma, Inc., acquired 3,768 shares of common stock on March 31, 2026.
- The acquisition was made at a price of $18.63 per share.
- Following this transaction, Lu Hongbo beneficially owns 426,736 shares.
- These shares are held indirectly through various entities, including NEXTBio Master Fund LP and NEXTBio Evergreen LLC, with Lu Hongbo having a pecuniary interest.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine share acquisition by a director without providing new financial or strategic information.
Positives
- Director acquisition of shares can signal confidence in the company's future prospects.
- The transaction indicates continued investment by insiders in the company's stock.
Future Outlook
No specific forward-looking statements or guidance are provided in this Form 4 filing.
Management Comments
- The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Industry Context
StockSavvy.ai notes that insider share acquisitions, particularly by directors, are common events in the biopharmaceutical sector as key personnel often align their financial interests with those of other shareholders. This filing provides transparency on such transactions.
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively, suggesting insider confidence, but the transaction size is relatively small in the context of total shares outstanding.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Transaction Date for share acquisition by Director Lu Hongbo. |
| 04/02/2026 | Signature Date of the filing. |
Keywords
Zenas BioPharma, Form 4, Insider Trading, Share Acquisition, Director, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.